Diabetes Board decisions

The Board granted service connection for coronary artery disease and diabetes mellitus, type 2 due to the Veteran's exposure to herbicide agents during his service in Korea. The claim for a brain tumor was remanded for further development.

The Board granted service connection for diabetes mellitus and hypertension based on new and relevant evidence, but remanded the claims for further development regarding the onset of these conditions during active duty or ACDUTRA.

The Board denied the claims for earlier effective dates, service connection for various conditions, and remanded some issues for further development.

The Board remands the claims for increased ratings due to duty to assist errors that occurred prior to the October 2023, December 2023, and January 2024 rating decisions on appeal.

The Board denied an earlier effective date for the Veteran's service-connected diabetes mellitus type 1, as no claim or intent to file a claim was received prior to April 21, 2023.

The Board denied the veteran's claims for increased ratings and service connection, finding that the evidence did not support higher ratings or service connection for any of the claimed conditions.

The Board denied a compensable rating for pseudofolliculitis barbae, dismissed the service connection claim for sleep disturbances as moot, and denied service connection claims for nonspecific neurological complaints, hemorrhoids, diabetes mellitus type II, and tinnitus.

The Board granted service connection for diabetes mellitus, finding the evidence to be approximately balanced as to exposure to herbicide agents and causation.

The Board remands all issues on appeal for additional development, including verification of potential exposure to herbicide agents and other chemicals, as well as obtaining any relevant treatment records.

The Veteran was granted a 70 percent disability rating for his service-connected PTSD and major depressive disorder from January 24, 2013 to September 6, 2016, but an increased rating of more than 100 percent is not available as a matter of law.

The Board granted service connection for obstructive sleep apnea (OSA) as secondary to the Veteran's service-connected depressive disorder with alcohol use disorder, but denied increased ratings and service connection for other conditions.

The Veteran's service-connected diabetes and upper and lower peripheral neuropathy rendered him unable to work in any job, sedentary or non-sedentary, making a total disability rating based on individual unemployability (TDIU) appropriate.

The Board remands the claims for service connection due to a pre-decisional duty to assist error regarding herbicide agent exposure.

The Board denied the Veteran's claims for an earlier effective date prior to August 10, 2022, for service connection for coronary artery disease and diabetes mellitus type II, as these conditions are subject to the PACT Act's effective date.

The Board denied an earlier effective date for the grant of service connection for diabetes mellitus, type II and a higher disability rating. The claims for service connection for peripheral neuropathy were remanded.

The Board denied the Veteran's claims for service connection for hypertension and diabetes mellitus, both secondary to his service-connected right ankle degenerative arthritis and bilateral shin splints.

The Board remands the claims for service connection for diabetes with diabetic residuals, sleep apnea, and hypertension to correct a duty to assist error that occurred prior to the September 2020 rating decision on appeal.

The Board granted service connection for Type II diabetes mellitus, finding it to be secondary to the Veteran's service-connected low back degenerative arthritis with intervertebral disc syndrome.

The Board granted service connection for diabetes mellitus, type II and Parkinson's disease based on the Veteran's exposure to herbicide agents during his service in Korea.

The Board denied an earlier effective date for service connection for diabetes, granted a 20 percent rating for diabetes from December 13, 2018, and granted service connection for bilateral lower extremity neuropathy with an effective date of October 23, 2021.